Trial Profile
A phase I, open-label, dose-escalation study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of INCB024360 in patients with advanced malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Epacadostat (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Incyte Corporation
- 04 Jan 2017 Results analysing safety, pharmacokinetics, pharmacodynamics and antitumor activity published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 19 Dec 2016 Results of population pharmacokinetic and pharmacodynamic modeling published in the Journal of Clinical Pharmacology
- 03 Jun 2013 Final results were presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).